显微外科乳房再造术后延长静脉血栓栓塞症化学预防:术后抗凝趋势分析
该研究利用PearlDiver数据库分析2010至2020年22606例接受显微外科乳房再造的乳腺癌患者,比较出院时接受与未接受门诊静脉血栓栓塞症(VTE)预防者的90天VTE风险。预防组356例(1.6%)无VTE发生,未预防组22250例(98.4%)中403例(1.8%)发生VTE,预防一例VTE需治疗55.25例。多数VTE事件(71.3%)发生于术后第10天之后。
要点
- 显微外科乳房再造术后多数VTE事件(71.3%)发生于术后第10天之后。
- 出院时接受门诊VTE预防者356例中无VTE发生,未预防者22250例中403例(1.8%)发生VTE。
- 预防一例VTE的需治疗人数为55.25例。
核心结论
- 乳房再造术后门诊化学预防使用不足,尽管多数VTE事件发生于急性术后期之后。
- 作者认为乳房显微外科医生应考虑将常规门诊化学预防作为术后护理路径的一部分以优化VTE预防。
研究设计与样本
- 将患者分为出院时接受任何形式门诊VTE预防组与未接受组,计算每组90天内VTE概率、绝对风险降低和需治疗人数。
- 采用假设二项分布的逻辑回归分析术后VTE事件相关的临床因素。
主要发现
- 2010至2020年共22606例患者接受显微外科乳房再造,其中356例(1.6%)出院时接受VTE预防,22250例(98.4%)未接受。
- 预防组无患者发生VTE,未预防组403例(1.8%)发生VTE。
- 预防一例VTE的需治疗人数为55.25例。
- 多数VTE事件(71.3%)发生于术后第10天之后。
临床怎么用
- 作者认为乳房显微外科医生应考虑将常规门诊化学预防作为术后护理路径的一部分以优化VTE预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microsurgical breast reconstruction following mastectomy represents a high-risk patient group for venous thromboembolism (VTE), but there is limited consensus on postoperative prophylaxis duration. The aim of this study was to characterize the risk of VTE after microsurgical breast reconstruction, the risk reduction associated with postoperative outpatient VTE prophylaxis, the clinical factors associated with VTE events, and surgeon prescribing patterns regarding outpatient VTE prophylaxis. METHODS: A commercially available database of 53 million unique patients, PearlDiver, was used to identify patients with breast cancer who underwent microsurgical breast reconstruction. Patients were grouped into those receiving any form of outpatient VTE prophylaxis at discharge and those who did not. Probability of VTE within 90 days was calculated for each group followed by absolute risk reduction and number needed to treat. A logistic regression, assuming binomial distribution, was performed to determine clinical factors associated with VTE events after surgery. RESULTS: A total of 22,606 patients underwent microsurgical breast reconstruction from 2010 to 2020. Of these patients, 356 (1.6%) were discharged with VTE prophylaxis and 22,250 (98.4%) were discharged without. No patients developed a VTE in the prophylaxis group, and 403 (1.8%) developed a VTE in the group without prophylaxis. The number needed to prevent one VTE was 55.25 patients. Most VTE events occurred after postoperative day 10 (71.3%). CONCLUSIONS: Outpatient chemoprophylaxis following breast reconstruction is underused despite the majority of VTE events occurring after the acute postoperative period. Breast microsurgeons should consider routine outpatient chemoprophylaxis as part of their postoperative care pathway to optimize VTE prevention. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Le ELH, Saifee J, Constantine R, et al. Extended Venous Thromboembolism Chemoprophylaxis following Microsurgical Breast Reconstruction: Analysis of Trends in Postoperative Anticoagulation. Plast Reconstr Surg. 2023. PMID: 36728476. doi:10.1097/PRS.0000000000010188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。